RayKnowChina Research Map
Shortlist0

GuiyangGuizhou Medical University

Affiliated Hospital of Guizhou Medical University

贵州医科大学附属医院

Listed for 19 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Affiliated Hospital of Guizhou Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌12 papers led
  2. Hepatocellular carcinoma肝细胞癌38 papers led
  3. Stomach cancer胃癌17 papers led
  4. Retinoblastoma视网膜母细胞瘤0 papers led
  5. Osteosarcoma骨肉瘤8 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  7. Neuroblastoma神经母细胞瘤4 papers led
  8. Ewing sarcoma尤文肉瘤1 paper led
  9. Multiple myeloma多发性骨髓瘤8 papers led
  10. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病4 papers led
  11. Beta thalassaemiaβ 地中海贫血1 paper led
  12. Haemophilia A血友病 A0 papers led
  13. Myasthenia gravis重症肌无力3 papers led
  14. Idiopathic pulmonary fibrosis特发性肺纤维化3 papers led
  15. Amyotrophic lateral sclerosis肌萎缩侧索硬化症3 papers led
  16. Behçet disease白塞病1 paper led
  17. Alport syndromeAlport 综合征1 paper led
  18. IgA nephropathyIgA 肾病0 papers led
  19. Hirschsprung disease先天性巨结肠1 paper led

Not listed for: Oesophageal squamous cell carcinoma, Hepatoblastoma, Chordoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 12 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
12
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 4420222023: 0020232024: 5520242025: 222025

2 hospitals in Guiyang for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
    Phase
    Phase 3
    Started
    2022-04
    Registry
    NCT05340491

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen

  2. Recruiting
    PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
    Phase
    Phase 3
    Started
    2020-03
    Registry
    NCT03907826

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrent / metastatic diseaseRadiotherapy techniqueInduction / concurrent chemotherapy
Departments in papersMedical oncologyENT / head & neck surgery

Over half of these papers are lab or animal studies.

Papers it led12
  1. High-dose radiation induces dendritic cells maturation by promoting immunogenic cell death in nasopharyngeal carcinoma.2025Frontiers in immunologyFree full text
  2. High-dose ionizing radiation-induced ferroptosis leads to radiotherapy sensitization of nasopharyngeal carcinoma.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  3. Research trends and hotspots in surgical treatment of recurrent nasopharyngeal carcinoma: A bibliometric analysis from 2000 to 2023.2024Asian journal of surgery
  4. Effect of immune-modulating metronomic capecitabine as an adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma.2024BMC immunologyFree full text
  5. Gemcitabine plus cisplatin versus docetaxel plus cisplatin and fluorouracil induction chemotherapy combined with locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A single center prospective phase II clinical trial.2024Oral oncologyRCT
  6. The circadian clock gene, BMAL1, promotes radiosensitization in nasopharyngeal carcinoma by inhibiting the epithelial-to-mesenchymal transition via the TGF-β1/Smads/Snail1 axis.2024Oral oncology
  7. Immunohistochemical Expression and Clinical Significance of WWP1 Protein in Nasopharyngeal Cancer.2024The journal of histochemistry and cytochemistry : official journal of the Histochemistry SocietyFree full text
  8. Long non-coding RNA RGMB-AS1 represses nasopharyngeal carcinoma progression via binding to forkhead box A1.2022BioengineeredFree full text
  9. Circadian clock gene BMAL1 inhibits the proliferation and tumor-formation ability of nasopharyngeal carcinoma cells and increases the sensitivity of radiotherapy.2022Chronobiology international
  10. EPHB2 as a recurrence-related gene and a prognostic indicator in nasopharyngeal carcinoma: A bioinformatics screening and immunohistochemistry verification.2022Histology and histopathology
  11. Overexpression of KITLG predicts unfavorable clinical outcomes and promotes lymph node metastasis via the JAK/STAT pathway in nasopharyngeal carcinoma.2022Laboratory investigation; a journal of technical methods and pathology
  12. Exosomal transfer of miR-106a-5p contributes to cisplatin resistance and tumorigenesis in nasopharyngeal carcinoma.2021Journal of cellular and molecular medicineFree full text
Chinese-language papers (not in the count)2
  1. [Expression of pepsin in nasopharyngeal carcinoma and its correlation with quality of life after radiotherapy].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  2. [The expression of clock gene CLOCK and its clinical significance in nasopharyngeal carcinoma].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status7
  1. Induction Chemotherapy Followed By Chrono-chemotherapy Concurrent With IMRT Of Locally Advanced NPC Clinical StudyStatus unknownNCT02187315Lead (inferred)Phase 2Start 2014-05
  2. Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III TrialRecruitingNCT05340491Study sitePhase 3Start 2022-04
  3. PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma PatientsRecruitingNCT03907826Study sitePhase 3Start 2020-03
  4. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03
  5. Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal CarcinomaActive, not recruitingNCT05211232Study sitePhase 3Start 2022-06
  6. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Study sitePhase 3Start 2021-08
  7. Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal CarcinomaStatus unknownNCT03321539Study sitePhase 3Start 2017-10
More papers found outside PubMed (not counted)25
  1. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Researchconference-abstract
  2. PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized2025Journal of Clinical Oncologyarticle
  3. Analysis of proliferating Treg cells as a predictor for immunotherapy response using systemic longitudinal immune profiling: Biomarker analysis of the phase 3 CONTINUUM trial.2024Journal of Clinical Oncologyconference-abstract
  4. Chronomodulated chemotherapy for locoregionally advanced nasopharyngeal carcinoma: A phase II randomized controlled trial2024Radiation Medicine and Protectionarticle
  5. Correlation of the biological clock gene PER1 with ferroptosis in nasopharyngeal carcinoma2024Biological Rhythm Researcharticle
  6. Expression of bromodomain-containing 4 in nasopharyngeal carcinoma: Clinicopathology, prognosis, immunity, and regulatory networks2024Journal of Laboratory Physiciansarticle
  7. Influence of intensity-modulated radiation therapy on long-term survival and late injury in patients with nasopharyngeal carcinoma after induction chemotherapy.2024Journal of Clinical Oncologyconference-abstract
  8. Long-term survival, toxicities, and the role of chrono-chemotherapy with different infusion rates in patients with locally advanced nasopharyngeal carcinoma treated with intensity-modulated radiation therapy: A retrospective study with a 5-2024Journal of Clinical Oncologyconference-abstract
  9. Nivolumab combined with chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): A multicenter, single-arm, phase II clinical trial.2024Journal of Clinical Oncologyconference-abstract
  10. Nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): An investigator-initiated, open-label, multicenter, single-arm, phase II clinical trial2024Journal of Clinical Oncologyconference-abstract
  11. The Correlation Study of Circadian Clock Gene Bmal1 on Growth Inhibition and Radiosensitivity in Subcutaneous Xenograft of Human Nasopharyngeal Carcinoma CNE1 in Nude Mice2024International Journal of Radiation Oncology*Biology*Physicsarticle
  12. The circadian clock gene BMAL1 increases radiosensitivity in nasopharyngeal carcinoma cell CNE22024Journal of Radiation Research and Applied Sciencesarticle
  13. The role and mechanism of circadian clock gene BMAL1 in the proliferation and metastasis of nasopharyngeal carcinoma by inhibition TGF-β1/Smads pathway.2024Journal of Clinical Oncologyconference-abstract
  14. Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomiz2024Journal of Clinical Oncologyconference-abstract
  15. Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.2023Journal of Clinical Oncologyconference-abstract
  16. Effects of biological clock gene BMAL1 and hypoxia-inducible factor HIF-1α on proliferation, migration and radiotherapy sensitivity of nasopharyngeal carcinoma cells HONE12023Holistic Integrative Oncologyarticle
  17. Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2023Journal of Clinical Oncologyconference-abstract
  18. Long-term follow-up results of the effects of chronotherapy and conventional chemotherapy combined with intensity modulated radiotherapy on dendritic cells and lymphocyte subsets in nasopharyngeal carcinoma.2022Journal of Clinical Oncologyconference-abstract
  19. TPF Induction Chemotherapy vs. PF Adjuvant Chemotherapy plus Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: A Multicenter, Randomized Controlled, III Trial2022International Journal of Radiation Oncology*Biology*Physicsarticle
  20. TPF induction chemotherapy versus PF adjuvant chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicenter, randomized controlled, III trial.2022Journal of Clinical Oncologyconference-abstract
  21. Associated with Immune Function, miR-150-5p is a Favorable Biomarker for Head and Neck Cancer Patients2021Research Squarepreprint
  22. Comparative Analysis of Clinical Results of Compared With TPF Induction of Chemotherapy and PF Adjuvant Chemotherapy Combined With Cisplatin Radiochemotherapy for Locally Advanced Nasopharyngeal Carcinoma2021International Journal of Radiation Oncology*Biology*Physicsarticle
  23. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.2021Journal of Clinical Oncologyconference-abstract
  24. The Correlation Study of Circadian Clock Gene BMAL1 Regulates the Biological Behavior of Human Nasopharyngeal Carcinoma Cell After Radiotherapy2021International Journal of Radiation Oncology*Biology*Physicsarticle
  25. We Hypothesize That BMAL1 Has a Positive Regulatory Effect on the Radiosensitivity of Nasopharyngeal Carcinoma2021International Journal of Radiation Oncology*Biology*Physicsarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 38 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
38
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 9920222023: 111120232024: 8820242025: 882025

1 hospital in Guiyang for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicinePediatricsMedical oncology

Over half of these papers are lab or animal studies.

Papers it led38
  1. Three-dimensional multimodal imaging for predicting early recurrence of hepatocellular carcinoma after surgical resection.2026Journal of advanced researchFree full text
  2. Identification and Validation of Basement Membrane Related LncRNA Signatures as a Novel Prognostic Model for Hepatocellular Carcinoma.2025Biochemical geneticsFree full text
  3. Kindlin-1 promotes mitophagy by inhibiting PINK1 degradation to enhance hepatocellular carcinoma progression and modulates sensitivity to donafenib.2025Cellular signalling
  4. YY1-mediated DUXAP8 facilitates HCC progression via modulating DEPDC1 expression.2025Clinical and experimental medicineFree full text
  5. Predicting hepatocellular carcinoma response to TACE: A machine learning study based on 2.5D CT imaging and deep features analysis.2025European journal of radiology
  6. IRX5 Promoted SREBP1-Mediated de Novo Fatty Acid Synthesis via HMGN4 in Hepatocellular Carcinoma.2025Journal of cellular and molecular medicineFree full text
  7. Glutamine reprogramming affects the tumor microenvironment and immune response in hepatocellular carcinoma.2025Molecular biology reports
  8. IL27RA promotes the proliferation and metastasis of hepatocellular carcinoma cells by regulating TGFβR1.2025Scientific reportsFree full text
  9. To construct and validate a risk score model of angiogenesis-related genes to predict the prognosis of hepatocellular carcinoma.2025Scientific reportsFree full text
  10. PPIH acts as a potential predictive biomarker for patients with common solid tumors.2024BMC cancerFree full text
  11. Transcriptomic and genomic characteristics of intrahepatic metastases of primary liver cancer.2024BMC cancerFree full text
  12. m1A regulator-mediated methylation modification patterns correlated with autophagy to predict the prognosis of hepatocellular carcinoma.2024BMC cancerFree full text
  13. The sorafenib resistance-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma.2024Cell cycle (Georgetown, Tex.)Free full text
  14. PRMT1-mediated methylation of ME2 promotes hepatocellular carcinoma growth by inhibiting ubiquitination.2024Cell death & diseaseFree full text
  15. Glycyrrhizic acid attenuates the malignant biological properties of nonalcoholic fatty liver disease-related hepatocellular carcinoma.2024Environmental toxicology
  16. Surgical Treatment After Conversion Therapy in a Patient With Massive Hepatocellular Carcinoma.2024Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates
  17. MIA3 promotes the degradation of GSH (glutathione) by binding to CHAC1, thereby promoting the progression of hepatocellular carcinoma.2024Molecular and cellular biochemistryFree full text
  18. Apoprotein E methylation is correlated with immune microenvironment in hepatocellular carcinoma.2023Acta oncologica (Stockholm, Sweden)
  19. PPIH gene regulation system and its prognostic significance in hepatocellular carcinoma: a comprehensive analysis.2023AgingFree full text
  20. Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis.2023BMC cancerFree full text
  21. TANGO1 interacts with NRTN to promote hepatocellular carcinoma progression by regulating the PI3K/AKT/mTOR signaling pathway.2023Biochemical pharmacology
  22. TM4SF1 upregulates MYH9 to activate the NOTCH pathway to promote cancer stemness and lenvatinib resistance in HCC.2023Biology directFree full text
  23. Immune landscape and immunotherapy of hepatocellular carcinoma: focus on innate and adaptive immune cells.2023Clinical and experimental medicineFree full text
  24. An inflammation-associated ferroptosis signature optimizes the diagnosis, prognosis evaluation and immunotherapy options in hepatocellular carcinoma.2023Journal of cellular and molecular medicineFree full text
  25. Aidi injection enhances the anti-tumor impact of doxorubicin in H22 tumor-containing mice.2023Journal of ethnopharmacology
  26. LHPP suppresses proliferation, migration, and invasion in hepatocellular carcinoma and pancreatic cancer by inhibiting EGFR signaling pathway.2023Medical oncology (Northwood, London, England)
  27. Silencing of peroxiredoxin 2 suppresses proliferation and Wnt/β-catenin pathway, and induces senescence in hepatocellular carcinoma.2023Oncology researchFree full text
  28. Prediction of 3-year recurrence rate of hepatocellular carcinoma after resection based on contrast-enhanced CT: a single-centre study.2023The British journal of radiologyFree full text
  29. NAP1L5 targeting combined with MYH9 Inhibit HCC progression through PI3K/AKT/mTOR signaling pathway.2022AgingFree full text
  30. Identification of MAD2L1 as a Potential Biomarker in Hepatocellular Carcinoma via Comprehensive Bioinformatics Analysis.2022BioMed research internationalFree full text
  31. Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3.2022BioengineeredFree full text
  32. DNASE1L3 inhibits proliferation, invasion and metastasis of hepatocellular carcinoma by interacting with β-catenin to promote its ubiquitin degradation pathway.2022Cell proliferationFree full text
  33. A Differentiation-Related Gene Prognostic Index Contributes to Prognosis and Immunotherapy Evaluation in Patients with Hepatocellular Carcinoma.2022CellsFree full text
  34. Aerobic glycolysis and tumor progression of hepatocellular carcinoma are mediated by ubiquitin of P53 K48-linked regulated by TRIM37.2022Experimental cell research
  35. WD repeat domain 48 promotes hepatocellular carcinoma progression by stabilizing c-Myc.2022Journal of cellular and molecular medicineFree full text
  36. Aidi injection altered the activity of CYP2D4, CYP1A2, CYP2C19, CYP3A2, CYP2E1 and CYP2C11 in normal and diethylnitrosamine-induced hepatocellular carcinoma in rats.2022Journal of ethnopharmacology
  37. circACTG1 Promotes Hepatocellular Carcinoma Progression by Regulating miR-940/RIF1 Axis and Activating AKT/mTOR Pathway.2022Journal of immunology researchFree full text
  38. CircC16orf62 promotes hepatocellular carcinoma progression through the miR-138-5p/PTK2/AKT axis.2021Cell death & diseaseFree full text
All its trials on ClinicalTrials.gov, any status2
  1. A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or AblationActive, not recruitingNCT04639180Study sitePhase 3Start 2021-04
  2. Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) PatientsStatus unknownNCT02956772Study sitePhase 2Start 2016-11

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 17 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
17
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 3320232024: 5520242025: 662025

1 hospital in Guiyang for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06632262

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseImmunotherapy & targeted drugsEarly detection & endoscopy
Departments in papersPathology / laboratory medicineGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)

Over half of these papers are lab or animal studies.

Papers it led17
  1. Juglone targets MMP-1 to inhibit gastric cancer progression.2025Biochemical pharmacology
  2. Case report: Local and systemic combination therapy: endoscopic injection of an oncolytic virus with PD-1 inhibitor for an elderly patient with advanced gastrointestinal cancer.2025Frontiers in immunologyFree full text
  3. Liquid-liquid phase separation in gastric cancer: identifying novel biomarkers and therapeutic targets through gene signature analysis.2025Frontiers in immunologyFree full text
  4. Identification of a tumor microenvironment-related gene signature for predicting prognosis in patients with gastric cancer.2025MedicineFree full text
  5. Super-enhancer-associated LINC00963 promotes metastasis of gastric cancer through epithelial-mesenchymal transition.2025PloS oneFree full text
  6. Study on the regulation of gastric cancer cell apoptosis by LACTB through mitochondrial autophagy pathway.2025Scientific reportsFree full text
  7. PPIH acts as a potential predictive biomarker for patients with common solid tumors.2024BMC cancerFree full text
  8. Short term efficacy and safety of PD-1 inhibitor and apatinib plus S-1 and oxaliplatin as neoadjuvant chemotherapy for patients with locally advanced gastric cancer.2024MedicineFree full text
  9. Long-term survival in a patient with multiple metastatic gastric cancer treated with PTX plus emvolimab and disitamab vedotin: case report and treatment experience: A case report.2024MedicineFree full text
  10. Gypenoside inhibits gastric cancer proliferation by suppressing glycolysis via the Hippo pathway.2024Scientific reportsFree full text
  11. Gastric Cancer Signaling Pathways and Therapeutic Applications.2024Technology in cancer research & treatmentFree full text
  12. A potential therapeutic approach for gastric cancer: inhibition of LACTB transcript 1.2023AgingFree full text
  13. CLDN5 identified as a biomarker for metastasis and immune infiltration in gastric cancer via pan-cancer analysis.2023AgingFree full text
  14. Super-enhancer-associated EEPD1 facilitates EMT-mediated metastasis by regulating the PI3K/AKT/mTOR pathway in gastric cancer.2023Biochemical and biophysical research communications
  15. Albumin Paclitaxel Compared with 5-Penfluorouracil, Lobaplatin, and Albumin Paclitaxel Combined with 5-Penfluorouracil in the Treatment of Human Gastric Cancer Cell AGS Line Autophagy and Apoptosis.2022Canadian journal of gastroenterology & hepatologyFree full text
  16. Interplay of Helicobacter pylori, fibroblasts, and cancer cells induces fibroblast activation and serpin E1 expression by cancer cells to promote gastric tumorigenesis.2022Journal of translational medicineFree full text
  17. SNHG16 lncRNAs are overexpressed and may be oncogenic in human gastric cancer by regulating cell cycle progression.2022Neoplasma
Chinese-language papers (not in the count)1
  1. [Application of posterior gastric mesentery in laparoscopic gastric surgery].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status4
  1. A Phase 2 Clinical Study of ABSK061 and ABSK043RecruitingNCT06632262Study sitePhase 2Start 2024-11
  2. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03
  3. Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerActive, not recruitingNCT04208347Study sitePhase 2/Phase 3Start 2019-12
  4. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led no English-language PubMed papers on retinoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Guiyang for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Long non-coding RNA XIST confers aggressive progression via miR-361-3p/STX17 in retinoblastoma cells.2020European review for medical and pharmacological sciences

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 8 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 2220232024: 1120242025: 332025

8 hospitals in Guiyang for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Over half of these papers are lab or animal studies.

Papers it led8
  1. Primitive Ewing Sarcoma of Epididymis: A Case Report and Literature Review.2025Journal of clinical ultrasound : JCU
  2. 124I-labelled BMSC-Derived Extracellular Vesicles Deliver CRISPR/Cas9 Ribonucleoproteins With a GFP-Reporter System to Inhibit Osteosarcoma Proliferation and Metastasis.2025Journal of extracellular vesicles
  3. MMP13 as an effective target of an active trifluoromethyl quinazoline compound against osteosarcoma.2025Toxicology and applied pharmacology
  4. MATN4 as a target gene of HIF-1α promotes the proliferation and metastasis of osteosarcoma.2024Aging
  5. KCNJ2/HIF1α positive-feedback loop promotes the metastasis of osteosarcoma.2023Cell communication and signaling : CCS
  6. Hsa_circ_0000073 promotes lipid synthesis of osteosarcoma through hsa-miR-1184/ FADS2 pathway.2023Cellular signalling
  7. A novel immune cell signature for predicting osteosarcoma prognosis and guiding therapy.2022Frontiers in immunology
  8. N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma.2022Technology in cancer research & treatment
Earlier papers (2016–2020)3
  1. Long non-coding RNA MALAT1 as a valuable biomarker for prognosis in osteosarcoma: A systematic review and meta-analysis.2019International journal of surgery (London, England)
  2. Correlation between TRAIL and caspase-8 expression and their relationship with cell proliferation and apoptosis in human osteosarcoma.2016Genetics and molecular research : GMR
  3. Diagnostic accuracy of CD44V6 for osteosarcoma: a meta-analysis.2016Journal of orthopaedic surgery and research

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Guiyang for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 4 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 1120242025: 002025

3 hospitals in Guiyang for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Guiyang for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Primitive Ewing Sarcoma of Epididymis: A Case Report and Literature Review.2025Journal of clinical ultrasound : JCU

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 8 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.5%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 4420242025: 222025

2 hospitals in Guiyang for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2023-10
    Registry
    NCT06049290

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Guiyang, Haikou, Hangzhou, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  3. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskRelapse & resistanceStem cell transplant
Departments in papersPediatricsClinical trials / research unit
Papers it led8
  1. Inflammatory Factors and Immune Cells in Relation to Multiple Myeloma.2025Acta haematologica
  2. Effects of mesenchymal stem cells from different sources on the biological functions of multiple myeloma cells.2025Stem cell research & therapyFree full text
  3. RAB22A as a predictor of exosome secretion in the progression and relapse of multiple myeloma.2024AgingFree full text
  4. Distinct pathway activities are associated with prognosis and response to bortezomib-containing treatment in MCL1-M based molecular subtypes of multiple myeloma.2024Annals of hematology
  5. Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma.2024Frontiers in immunologyFree full text
  6. Circulating exosomal miRNA-451 as an effective diagnostic biomarker and prognostic indicator for multiple myeloma.2024The International journal of biological markers
  7. Identification of an Autophagy-Related Signature Based on Whole Bone Marrow Sequencing for the Prognosis and Immune Microenvironment Characterization of Multiple Myeloma.2022Journal of immunology researchFree full text
  8. C3a and C5a facilitates the metastasis of myeloma cells by activating Nrf2.2021Cancer gene therapy
All its trials on ClinicalTrials.gov, any status3
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  2. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  3. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple MyelomaRecruitingNCT06049290Study sitePhase 1/Phase 2Start 2023-10

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 4 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 1.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 2220242025: 112025

1 hospital in Guiyang for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Registry
    NCT06764238

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 24 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi'an

  2. Recruiting
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06882057

    Age 1 year to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 23 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an

  3. Recruiting
    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT07152041

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 20 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan

  4. Recruiting
    Study of YK012 in B-cell Acute Lymphoblastic Leukemia
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06580301

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangchun, Guangzhou, Guiyang, Hangzhou, Nanchang, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPhiladelphia chromosome & geneticsChildrenStem cell transplant

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

5 hospitals in Guiyang for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Papers it led1
  1. Molecular Characterization of α- and β-Thalassemia Among Children Less Than 18 Years Old in Guizhou, China.2024Journal of clinical laboratory analysis
Earlier papers (2016–2020)1
  1. From the Pharynx to the Brain: A Case of Rapidly Progressing Mucormycosis.2019Mycopathologia
All its trials on ClinicalTrials.gov, any status1
  1. Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-ThalassaemiaCompletedNCT04390971Study siteN/AStart 2023-02

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution

2 hospitals in Guiyang for haemophilia A160 hospitals in China for haemophilia A

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
    Phase
    Phase 2/Phase 3
    Started
    2024-01
    Registry
    NCT06111638

    Age 18 years to Not stated; men only (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Guiyang, Kunming, Suzhou, Tianjin, Wuhan, Xi’an

  2. Recruiting
    Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
    Phase
    Phase 3
    Started
    2021-11
    Registry
    NCT05145127

    Age 1 year to 74 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Guangzhou, Guiyang, Nanchang, Tianjin, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status9
  1. Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy DrugsRecruitingNCT06111638Study sitePhase 2/Phase 3Start 2024-01
  2. Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without InhibitorsRecruitingNCT05145127Study sitePhase 3Start 2021-11
  3. Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia ANot yet recruitingNCT06136507Study sitePhase 3Start 2026-12
  4. A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BRecruitingNCT05611801Study sitePhase 3Start 2022-12
  5. Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)CompletedNCT05082116Study sitePhase 3Start 2021-09
  6. Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia ACompletedNCT04845399Study sitePhase 3Start 2021-04
  7. Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia BCompletedNCT03938792Study sitePhase 3Start 2020-03
  8. An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.CompletedNCT04456387Study sitePhase 3Start 2020-10
  9. PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia ACompletedNCT02492984Study sitePhase 4Start 2015-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 3 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.6%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

1 hospital in Guiyang for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
    Phase
    Phase 1
    Started
    2025-09
    Registry
    NCT07215650

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChangchun, Chengdu, Guangzhou, Guiyang, Shanghai, Taiyuan, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurologyPediatrics
Papers it led3
  1. BMSCs-Derived Extracellular VesiclemiR-29a-3p Improved the Stability of Rat Myasthenia Gravis by Regulating Treg/Th17 Cells.2024Immunological investigations
  2. Nonlinear relationship between circulating natural killer cell count and 1-year relapse rates in myasthenia gravis: a retrospective cohort study.2024PeerJFree full text
  3. Safety of SARS-CoV-2 vaccines in patients with myasthenia gravis: a meta-analysis.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical NeurophysiologyFree full text
Chinese-language papers (not in the count)2
  1. [Detection of memory T cells, follicular T cells and relevant cytokines in the peripheral blood of patients with myasthenia gravis during treatment].2022Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  2. [Two cases of myasthenia gravis with positive anti-acetylcholine receptor antibody and anti-voltage gated calcium channel antibody].2022Zhonghua er ke za zhi = Chinese journal of pediatrics
All its trials on ClinicalTrials.gov, any status3
  1. Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)RecruitingNCT07215650Study sitePhase 1Start 2025-09
  2. A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia GravisActive, not recruitingNCT06298552Study sitePhase 3Start 2024-04
  3. A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia GravisTerminatedNCT04963270Study sitePhase 3Start 2021-10

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 3 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 112025

2 hospitals in Guiyang for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 3 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.4%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

3 hospitals in Guiyang for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Guiyang for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led 1 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Guiyang for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Guiyang for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of SGB-9768 in Patients With Complement-mediated Kidney DiseasesActive, not recruitingNCT06786338Study sitePhase 2Start 2025-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 1 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Guiyang for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

贵州医科大学附属医院

Affiliated Hospital of Guizhou Medical University

贵阳

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Guizhou Cancer Hospital; Second Affiliated Hospital of Guizhou Medical University; Guizhou Cancer Center; affiliated hospital of Guizhou medical university; Guizhou Cancer Hospital of Guizhou Medical University

Suggest a correctionDownload the data